The Glycemic Efficacy and Safety Profile of Gliptins: Updated Data in 2020

Abstract

Background: The earlier update on the safety of gliptins published in 2018 showed that dipeptidyl peptidase-4 (DPP-4)
inhibitors have good tolerance and safety profile even in susceptible populations. This review provides recent updates
(2018‑2020) on the glycemic efficacy and safety profile of gliptins, cardiovascualr safety of gliptins, and their role when used
early in diabetes therapy. Summary: DPP-4 inhibitors or gliptins is an established class of oral antidiabetic agents in the
management of type 2 diabetes with proven efficacy and safety profiles in adults, elderly and young patients. The excellent
safety and efficacy of DPP-4 inhibitors are established in type 2 diabetes management even in fragile populations and
individuals with varying degrees of renal dysfunction. DPP-4 inhibitors are associated with a good tolerability profile and
reduced risk of hypoglycemia. Studies have not shown the involvement of gliptins in cardiovascular adverse events and are
considered to be safe for use in terms of cardiovascular events.